Compare NBTB & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBTB | SYRE |
|---|---|---|
| Founded | 1856 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.6B |
| IPO Year | N/A | 2016 |
| Metric | NBTB | SYRE |
|---|---|---|
| Price | $46.44 | $34.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $51.00 | ★ $56.50 |
| AVG Volume (30 Days) | 211.5K | ★ 569.5K |
| Earning Date | 01-26-2026 | 02-26-2026 |
| Dividend Yield | ★ 3.19% | N/A |
| EPS Growth | ★ 12.12 | N/A |
| EPS | ★ 3.33 | N/A |
| Revenue | ★ $678,339,000.00 | N/A |
| Revenue This Year | $14.85 | N/A |
| Revenue Next Year | $6.02 | N/A |
| P/E Ratio | $13.93 | ★ N/A |
| Revenue Growth | ★ 21.71 | N/A |
| 52 Week Low | $37.31 | $10.91 |
| 52 Week High | $49.18 | $35.31 |
| Indicator | NBTB | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 65.66 | 57.61 |
| Support Level | $41.87 | $30.92 |
| Resistance Level | $44.86 | $34.07 |
| Average True Range (ATR) | 1.36 | 1.80 |
| MACD | 0.26 | -0.03 |
| Stochastic Oscillator | 92.38 | 78.41 |
NBT Bancorp Inc is a financial holding company that operates through its subsidiaries. The company's principal sources of revenue include management fees and dividends it receives through its subsidiaries. Its business, predominantly conducted through NBT Bank, consists of providing commercial banking, retail banking, and wealth management services to customers in its market area, which includes upstate New York, northeastern Pennsylvania, southern New Hampshire, western Massachusetts, Vermont, southern Maine, and central and northwestern Connecticut. The company's reportable segments are Banking and Retirement Plan Administration. A majority of its revenue is generated from the Banking segment.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.